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http://www.actaneurocomms.org/content/2/1/152RESEARCH Open AccessThe prion protein protease sensitivity, stability and
seeding activity in variably protease sensitive
prionopathy brain tissue suggests molecular
overlaps with sporadic Creutzfeldt-Jakob disease
Alexander H Peden*, Deep P Sarode, Carl R Mulholland, Marcelo A Barria, Diane L Ritchie, James W Ironside
and Mark W HeadAbstract
Introduction: Variably protease sensitive prionopathy (VPSPr) is a recently described, sporadic human prion disease
that is pathologically and biochemically distinct from the currently recognised sporadic Creutzfeldt-Jakob disease
(sCJD) subtypes. The defining biochemical features of the abnormal form of the prion protein (PrPSc) in VPSPr are
increased sensitivity to proteolysis and the presence of an N- and C-terminally cleaved ~8 kDa protease resistant PrPSc
(PrPres) fragment. The biochemical and neuropathological profile of VPSPr has been proposed to resemble either
Gerstmann–Sträussler–Scheinker syndrome (GSS) or familial CJD with the PRNP-V180I mutation. However, in some
cases of VPSPr two protease resistant bands have been observed in Western blots that co-migrate with those of
type 2 PrPres, suggesting that a proportion of the PrPSc present in VPSPr has properties similar to those of sCJD.
Results: Here, we have used conformation dependent immunoassay to confirm the presence of PrPSc in VPSPr
that is more protease sensitive compared with sCJD. However, CDI also shows that a proportion of PrPSc in VPSPr
resists PK digestion of its C-terminus, distinguishing it from GSS associated with ~8 kDa PrPres, and showing similarity to
sCJD. Intensive investigation of a single VPSPr case with frozen tissue from multiple brain regions shows a broad,
region-specific spectrum of protease sensitivity and differential stability of PrPSc in the absence of PK treatment. Finally,
using protein misfolding cyclic amplification and real-time quaking induced conversion, we show that VPSPr PrPSc has
the potential to seed conversion in vitro and that seeding activity is dispersed through a broad range of aggregate
sizes. We further propose that seeding activity is associated with the ~19 and ~23 kDa PrPres rather than the ~8 kDa
fragment.
Conclusions: Therefore, PrPSc in VPSPr is heterogeneous in terms of protease sensitivity and stability to denaturation
with the chaotrope GdnHCl and includes a proportion with similar properties to that found in sCJD.
Keywords: Variably protease resistant prionopathy, VPSPr, Prion, PrP, PrPSc, Gerstmann–Sträussler–Scheinker syndrome
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Human prion diseases are invariably fatal neurodegenera-
tive disorders that include sporadic, genetic and acquired
forms. The phenotypic and strain-related properties of hu-
man prion diseases are, according to the prion hypothesis,
enciphered in the conformation of the misfolded, disease
associated isoform of the prion protein, PrPSc (Table 1),
which is partially protease resistant and accumulates in the
brains of patients with disorders such as Creutzfeldt-Jakob
disease and Gerstmann-Sträussler-Scheinker syndrome
(GSS). Molecular strain typing has focused extensively
on differences in the fragment size and glycosylation site
occupancy of PrPres, the proteinase resistant core of PrPSc
(Table 1) resulting from limited digestion with proteinase
K (PK). Although defined by clinico-pathological criteria,
different subtypes of human prion disease can be classified
using these PrPres molecular profiles in conjunction
with the presence of mutations and polymorphisms in
the prion protein gene (PRNP). For example, in sporadic
CJD (sCJD) six molecular subtypes have been defined that
combine the PRNP codon-129 genotype polymorphism
(MM, MV or VV) with the apparent molecular mass of
the unglycosylated protease resistant fragment of PrPres
on western blots which is either 21 kDa (type 1) or 19 kDa
(type 2A), according to the nomenclature of Parchi and
Gambetti [1]. In addition, other PrPSc fragment sizes have
been noted in association with other human prion diseases,
e.g. GSS with the P102L mutation in PRNP, in which either
type 1 PrPres or a low molecular mass ~8 kDa PrPres frag-
ment can predominate [2].
Variably protease-sensitive prionopathy (VPSPr) is a
novel sporadic human prion disease that was first reported
in the USA in 2008 [3]. Further cases of VPSPr have been
identified prospectively and retrospectively in the USA [4],
UK [5-7], the Netherlands [8] and Spain [9,10]. VPSPr hasTable 1 Abbreviations used throughout
Abbreviation Definition
PrPSc The abnormal, disease-assoc
disease and species in whic
decreased solubility and inc
the protein and self-aggreg
PrPC Normal form of the prion p
PrPres Protease resistant core of Pr
~8 kDa PrPres fragment Low molecular mass PrPres
with 50 μg/ml PK in brain t
senPrPSc The component of PrPSc tha
CDI Conformation dependent im
GSS Gerstmann-Sträussler-Schein
GSS (~8 kDa PrPres) GSS case associated with a
analysed by western blottin
GSS (type 1 PrPres) GSS case characterised by t
by western blotting followina distinctive neuropathology characterised by the presence
of microplaques, but it is essentially defined by the bio-
chemistry of PrPSc in the brain that is less resistant to
proteases than the PrPSc in other human prion diseases,
and the presence of N- and C-terminally cleaved ~8 kDa
PrPres. In these respects VPSPr has been proposed to
resemble GSS [4,8], although a comparison has also been
drawn with familial CJD associated with the V180I-129 M
haplotype, with respect to the absence of diglycosylated
PrPres and the presence of ~8 kDa PrPres [11]. Alterna-
tively, we and others have identified regional heterogeneity
in the PrPres profile in some VPSPr brains, specifically the
presence of bands with mobilities very similar to type 2A
PrPres in VPSPr cerebellum, an observation that suggests
that a proportion of the PrPSc present has properties simi-
lar to those found in sCJD [3,7,10].
In this paper, we have employed conformation
dependent immunoassay (CDI), to characterise the
physicochemical properties of PrPSc in VPSPr brain.
CDI can sensitively detect both protease-sensitive
PrPSc (senPrPSc) and protease resistant PrPSc (PrPres) with
intact C-termini, and can measure the conformational
stability of PrPSc isoforms to guanidine denaturation
when no PK is used. CDI detects PrPSc on the basis of
an increase in signal following denaturation with guan-
idine HCl, because epitopes hidden within the structure
of PrPSc become exposed in the presence of this chaotro-
pic salt. In practice, for CDI to efficiently detect PrPSc a
preparative step, such as NaPTA precipitation, mild prote-
olysis (≤2.5 μg/ml PK) or centrifugal concentration is usu-
ally necessary, in order to remove PrPC [12-14]. We have
performed the above analyses comparing VPSPr to sCJD
and GSS focussing on aspects of the regional variability of
PrPSc in terms of protease resistance and stability. These
analyses have been done in order to aid our understandingiated form (generically termed the scrapie isoform, irrespective of the
h it occurs) which is characterised by increased β-pleated sheet content,
reased protease-resistance compared with PrPC as a result of refolding of
ation.
rotein as expressed in the central nervous system and other tissues.
PSc detected by western blotting following treatment with 50 μg/ml PK.
fragment of ~8 kDa detected by western blotting following treatment
issue from patients with VPSPr and some patients with GSS.
t is poorly resistant to protease treatment (i.e. >2.5 μg/ml PK)
munoassay
ker syndrome
low molecular mass fragment of PrPres of approximately ~8 kDa when
g following proteinase K digestion.
he presence of 20-30 kDa type 1 PrPres fragments in brain when analysed
g proteinase K digestion.
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the molecular level. We have also investigated whether
there are any regional differences in the way VPSPr PrPSc
behaves in a cell-free conversion assay, protein misfolding
cyclic amplification (PMCA). Having previously shown
that brain homogenates of all sCJD subtypes can efficiently
seed real-time quaking induced conversion (RT-QuIC) at
levels equivalent to femto grams (1x10-15 g) of PrPres, we
also compared the seeding potential of differently sized
PrPSc aggregates in VPSPr and sCJD by RT-QuIC [15].
Materials and methods
Tissues used in this study
This study was limited by the availability of frozen tissue
with consent for research from VPSPr cases. We have
identified nine cases of VPSPr in total over the surveil-
lance period 1991-present, disproportionately affecting
individuals who are VV at PRNP codon-129. Table 2
summarises the frozen tissue available for this study.
No MM cases and only one MV case had frozen tissue
available for research. In only one of the four VV cases
(case 1) was a complete half brain taken at autopsy with
consent for research.
In addition, three sporadic Creutzfeldt–Jakob disease
(sCJD) cases (MM1, MM2 and VV2 subtypes), one variant
CJD case (vCJD), two Gerstmann–Straüssler–Scheinker
disease (GSS) cases (both P102L mutation), and 10 control
(non-prion disease) cases were analysed in this study. Five
of the latter control cases, from the MRC Edinburgh CJD
Brain and Tissue bank, had been considered for a clinical
diagnosis of human prion disease, but an alternative
pathological diagnosis was reached. The other five cases,
from the MRC Sudden Death Brain and Tissue bank, had
no neurological or neuropathological evidence of disease.
All cases used were of UK origin. The tissues were collected
with consent for research, and the study was conducted
under research ethics approval (11/ES/0022, Edinburgh
Brain Bank).
Immunohistochemistry
VPSPr cases in this study were reviewed by immunohis-
tochemical analysis for PrP using the anti-PrP antibodiesTable 2 Summary of the five VPSPr cases used in this study
VPSPr case number
(in this study)
PRNP-codon
129 genotype
References Froz
(Abb
1 VV This study FC, T
Midb
2 VV [7] (Case 4) FC, C
3 VV [7] (Case 3) FC, C
4 VV [5] FC, C
5 MV [6] FC3F4, 12F10, KG9 and 6H4 as described previously [7]. A
semi-quantitative estimation was made on the relative
density of microplaques within the molecular layer of
the cerebellum in all five cases of VPSPr using the 3F4
antibody; sections were reviewed independently by two
experienced reviewers (DLR, JWI) using a four point scale
with 0 being absent and 3+ being severe (see Table 2).
Homogenization of brain samples for conformation
dependent immunoassay (CDI) analysis
Frozen tissue samples were weighed and homogenised
in phosphate buffered saline containing 2%N-lauroylsar-
cosine, to a final tissue concentration of 10% (wt/vol)
using a Fastprep machine (MP Biomedical, CA, USA) as
described by us previously [12]. The homogenates were
then cleared of cellular debris by centrifugation at 5200 g
for five minutes at 4°C.
Detection of PrPSc by CDI
We used a 96-well plate based conformation-dependent
immunoassay (CDI) to characterise the physicochemical
properties of PrPSc in VPSPr and the controls mentioned
above. The CDI method used has been described previ-
ously [13]. CDI resembles a sandwich ELISA but it
involves a capture antibody, MAR-1, which binds both
the native and denatured forms of the normal prion pro-
tein, PrPc (Table 1), and the abnormal, disease-associated
prion protein, PrPSc. However, the detection antibody
(europium-labelled 3F4) binds both native and denatured
PrPc, but only binds to PrPSc after it has been denatured
by guanidine hydrochloride (GdnHCl). Therefore, the
signal detected when the sample is denatured (D)
minus the signal for the native samples (N) can be used
as a quantitative measure of PrPSc.
For PrPSc to be detected by CDI, the MAR-1 and 3F4
epitopes must be intact and not subject to proteolytic
processing in either conformer. Due to the position of
the MAR-1 capture epitope, only PrPSc with an intact
C-terminus is detectable by CDI (Figure 1a). The ~8 kDa
fragment observed in VPSPr by western blot following
proteinase K digestion (Figure 1b) lacks that C-terminal
epitope for the MAR-1 antibody and is undetectable byen tissues available
reviations as in Figure 5.)
Semi-quantitative score for the
presence of microplaques in the
cerebellum 0 = absent 3+ = severe
C, PC, OC, Cb, Hip,Thal,
rain, Pons, Me
1+
b 3+
b, TC 1+
b 3+
0
Human PrP
aa23 aa231
S S
N C
18-30kDa PrPres fragments
8kDa fragment
MAR-1
3F4
type 1 
type 2 
sCJD
Type 1 Type 2
VPSPr
Diglycosylated
Monoglycosylated
Unglycosylated
23 kDa
19 kDa
8 kDa
18-30 kDa
molecular mass 
range
<10 kDa
molecular mass 
range
a
b
Figure 1 Human PrP primary structure. (a) Schematic diagram of human PrP primary structure showing the location of epitopes for the MAR-1
capture antibody (used in CDI) and the 3F4 detection antibody (used in CDI and western blotting) and the regions corresponding to the 18-30 kDa
PrPres bands and the ~8 kDa PrPres band. Blue circles indicate the position of the glycan moieties at amino acids 181 and 197. Note that MAR-1 epitope
is discontinuous and depends on an intact C-terminal disulphide bond, which is absent from the ~8 kDa PrPres fragment seen in cases of VPSPr.
Due to the position of the MAR-1 capture epitope, only PrPSc with an intact C-terminus is detectable by CDI. (b) Schematic diagram indicating
the approximate migration positions of bands obtained when samples from sCJD brain or VPSPr brain are treated with PK and analysed by
immunoblotting using the anti-PrP monoclonal antibody 3F4 (epitope amino acids 106-112). The upper ~19 and ~23 kDa bands observed in
some VPSPr cases have mobilities similar the unglycosylated and monoglycosylated bands of type 2A PrPres in sCJD.
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from some VPSPr cases at ~19 and ~23 kDa which may
directly correspond to the mono- and unglycosylated
bands of sCJD with type 2 PrPres (Figure 1b) are detectable
using antibodies that recognise C-terminal epitopes in
PrP (Additional file 1: Figure S1). Therefore, these pro-
tease resistant fragments may be detectable by CDI.
Homogenates (10% w/v) from all tissues used in this
study (see above) were either assayed by CDI directly, or
following limited proteolytic digestion with 1, 2.5, 10 or
50 μg/ml PK for 1 h at 37°C. PK digestion was terminated
by the addition of 1 mM Pefabloc SC. Homogenates were
divided into two equal aliquots. One aliquot was mixed
with an equal volume of 8 M guanidine hydrochloride
(GdnHCl) and denatured (D) by incubating at 81°C for six
minutes and the other was diluted without GdnHCl
and left at room temperature and designated native
(N). The remainder of the CDI method used in this
study was performed as described previously [13] using the
dissociation enhanced lanthanide fluorescence immuno-
assay technology (DELFIA™, PerkinElmer, Cambridge,
UK). Both D and N samples were adjusted to a final
volume of 650 μl and a final guanidine concentration of
308 mM, with water containing complete™ EDTA-free
protease inhibitors (Roche, Hertfordshire, UK). Theanti-PrP capture antibody MAR-1 (a generous gift from
Dr Albrecht Gröner, CSL Behring, Marburg, Germany)
was used at 0.5 μg/well. The wells were washed with
DELFIA wash buffer (PerkinElmer). After saturating the
plate by shaking for 1 h with 0.5% (wt/vol) bovine serum
albumin and 6% D-sorbitol (wt/vol) in DELFIA wash
buffer, the wells were washed and the D or N samples
were loaded in triplicate onto the plate (200 μl/well) and
incubated for 2 h at 20°C with shaking.
After washing the plate, europium-conjugated anti-PrP
antibody 3F4 (~25 ng/ml) in DELFIA assay buffer
(200 μl/well) was added to all wells and incubated for
2 h at 20°C with shaking. The wells were then washed
six times and DELFIA enhancement solution (200 μl/well)
was added to all wells. After incubation for five minutes at
20°C with shaking, the time-resolved fluorescence signals
for the denatured and native samples were measured
using a Victor 2 fluorometer (PerkinElmer).
The value obtained from the denatured sample (D)
represents the detection of total PrP i.e. PrPC + PrPSc.
The value obtained for the native sample (N), without
denaturation, represents PrPC. Therefore, D-N is directly
proportional to PrPSc. In reality, there may be a small in-
crease in the accessibility of the 3F4 epitope in unfolded
PrPC versus native PrPC. Therefore, to be effective, a
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PrPC prior to analysis.
Calibration of CDI
The CDI assay for PrP was calibrated using full-length
human recombinant PrP (recHuPrP, amino acids 23-231,
methionine at codon 129) purified as described previously
[15]. A range of dilutions from 40 μg/ml to 10 μg/ml of
this recHuPrP was prepared using PBS containing 2%
sarkosyl. Twenty-five μl samples of these dilutions were
mixed with an equal volume of 8 M GdnHCl and dena-
tured as described above. These samples were adjusted
to 650 μl, with water containing complete™ EDTA-free
protease inhibitors and analysed as described above.
The time resolved fluorescence counts obtained for the
recHuPrP dilution series were used to plot a standard
curve of counts versus micrograms of PrP. This curve
was used to convert the ‘D’ and ‘N’ CDI signals obtained
for known volumes of 10% (wt/vol) brain homogenates
into values with units of micrograms of PrP per gram of
brain tissue.
Equilibrium unfolding for the analysis of PrPSc stability
Stability analysis of the PrPSc conformer was performed
on two cases of GSS with the P102L mutation (one associ-
ated with an ~8 kDa PrPres and the other associated with
the typical three-band type 1 PrPres following western blot
analysis) and on various brain regions from VPSPr case 1,
for which multiple brain regions were available (Table 2).
Frontal cortex and cerebellum from a case of sCJD (VV2
subtype) and two cases of GSS were analysed as controls.
To concentrate PrPSc, the brain tissue homogenates
(100 μl) were centrifuged (1 h at 20,000 g at 4°C) [16].
The pellets were resuspended in 50 μl of 0.1% N-laur-
oylsarcosine/PBS containing complete™ EDTA-free pro-
tease inhibitors and a range of GdnHCl concentrations
from 0 to 4 M or 6 M and incubated with shaking
(~500 rpm) overnight at 20°C. The samples were ad-
justed to a final volume of 650 μl and then loaded onto
MAR-1 coated plates and analysed by DELFIA™ using
Eu-3F4 as described above. The data were normalised to
‘fraction of PrPSc unfolded’ by adjusting the value obtained
without denaturation (0 M GdnHCl) to zero and the max-
imum value to 1. The data were analysed by non-linear
regression assuming a sigmoidal relationship between
GdnHCl concentration and the fraction of PrPSc unfolded.
Western blotting
The western blot method that was used to analyse the
multiple brain regions from VPSPr case 1 has been de-
scribed previously [17]. The protocol used was one spe-
cifically designed to detect poorly protease-resistant PrP
that occurs in the form of a ~8 kDa band in cases with
variably protease-sensitive prionopathy. For western blotanalysis, samples were homogenized to 10% (w/v) in tris-
buffered saline, pH 7.6, containing 0.5% Nonidet P40 and
0.5% sodium deoxycholate and cleared by centrifugation
at 400 g for 5 min. Aliquots of the cleared 10% brain
homogenates were subjected to limited proteolysis with
PK at 50 μg/ml for 1 h at 37°C terminated with 1 mM
Pefabloc SC (Roche, Burgess Hill, UK). Unless otherwise
stated, maximal volumes of 24 μl were loaded onto the
gel. Polyacrylamide gel electrophoresis and Western blot-
ting was performed using the NuPAGE Novex gel system
(Life Technologies, Paisley, UK). The gel electrophoresis
time was shortened to retain low molecular mass proteins
[5,8]. The immunodetection of PrP was achieved using
the monoclonal antibodies 3F4 (epitope 106-112, from
Millipore, Watford, UK) at final concentrations of 75 ng/ml
or 94B4 (epitope 187-194, from Central Veterinary Institute
of Wageningen UR, Lelystad, The Netherlands) at a
concentration of 1:5000 for 1 h. The secondary antibody
used was ECL Mouse IgG, HRP-linked whole Ab (GE
Healthcare Life Sciences, Amersham, United Kingdom).
The detection reagent employed was Amersham ECL
Prime western Blotting Detection Reagent (GE Healthcare
Life Sciences). The blots were imaged and analysed by
densitometry using the ChemiDoc™ XRS + System with
Image Lab™ Software (Bio-Rad, Hemel Hempstead, UK).
Protein misfolding cyclic amplification (PMCA)
PMCA was carried out as described previously [18].
VPSPr cases 2 and 3, both VV at PRNP-codon 129, were
selected in which a distinction had been observed in the
western blot PrPres pattern between the frontal cortex
(predominantly ~8 kDa fragment) and the cerebellum
(bands of 18-30 kDa, in a pattern similar to type 2A).
The two VPSPr cases, numbered 2 and 3 in this study,
correspond to cases 4 and 3, respectively, in the retrospect-
ive review of UK cases (Table 2) [7]. Brain homogenate was
prepared from the frontal cortex (FC) and cerebellum (Cb)
of VPSPr cases 2 and 3 for use as seeds. For comparison,
PMCA was also carried out on frontal cortex tissue from a
case of sCJD (VV2 subtype) and two cases of GSS with the
P102L mutation, one associated with ~8 kDa and the other
associated with type 1 PrPres. The brain homogenates used
as substrates were prepared from either frontal cortex of
non-CJD patients, or humanised transgenic mouse brain,
with compatible PRNP-codon 129 genotypes (VV in the
case of VPSPr and sCJD VV2 subtype) and MM for both
cases of GSS). The (seed:substrate) volume ratios were as
follows: VPSPr cases (1:4), GSS and sCJD cases (1:9). Low
molecular mass heparin (100 μg/ml) was included in all
PMCA reactions [19].
Real-time quaking induced conversion (RT-QuIC)
We used RT-QuIC to examine the seeding activity of
VPSPr case 1, versus a sCJD VV2 case and a non-CJD
0
100
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900
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Figure 2 Comparison of the D-N values in brain frontal cortex
from cases of VPSPr, sCJD MM1, sCJD MM2, sCJD VV2, vCJD,
two GSS cases and non-CJD. (a) The D-N values for VPSPr patients
are the means (+/- S.D.) of five patients, whereas the values for
non-CJD are from ten patients, five being cases of sudden death,
three Alzheimer’s disease, one cerebral infarction and one motor
neurone disease/frontal lobe dementia. Also shown for comparison,
are D-N values for individual patients with vCJD (MM2B), sCJD subtypes
MM1 and MM2, and VV2, and two cases of GSS with the P102L
mutation of PRNP, one GSS (~8 kDa) and the other GSS (type 1). For
the latter results from individual patients, the D-N values are the means
(+/- S.D.) of triplicate analyses of single samples. (b) The D-N values
(log10 scale) are shown for the same brain frontal cortex samples as in
(a), but additionally D-N values obtained after treating the homogenates
with no PK (red bars) are compared with the values obtained after 2.5
or 50 μg/ml PK (green and blue bars), respectively.
Peden et al. Acta Neuropathologica Communications 2014, 2:152 Page 6 of 17
http://www.actaneurocomms.org/content/2/1/152case (amyotrophic lateral sclerosis with frontotemporal
lobar dementia). The method used for the RT-QuIC
in vitro conversion assay was as described previously
[15] with some modifications. Full length hamster recom-
binant PrP (aa 23–231; GenBank accession no. K02234)
was exclusively used as a substrate. This was expressed
and purified as described previously [15], and provided by
Dr Gary Mallinson, NHS Blood and Transplant, Bristol,
UK. Brain seeds were prepared by homogenising frozen
tissue samples using a Fastprep machine (as described
above) in PBS containing 1 mM EDTA, 150 mM NaCl,
0.5% Triton X-100 and Complete Mini EDTA-free Pro-
tease Inhibitor Cocktail (Roche) to give a final tissue
concentration of 10% (w/v). The amounts of brain
homogenate introduced into the RT-QuIC assays were
normalized according to the concentration of PrPres
determined by quantitative analysis of western blots in
which brain samples had been run against known
amounts of recombinant PrP [15]. Dilutions of the brain
homogenates were performed using PBS containing 0.1%
sodium dodecyl sulphate (SDS). The RT-QuIC reactions
were a final volume of 100 μl and contained recombinant
PrP at a final concentration of 0.1 mg/ml. The reactions
were initiated by the addition of 2 μl of the appropriately
diluted seed. The plates were incubated at 42°C and
shaken intermittently at 900 r.p.m. (87 sec shaking,
33 min at rest) using a FLUOstar OMEGA microplate
reader (BMG Labtech) in a double orbital configuration.
Fluorescence readings were taken at 480 nm every 15 min
from the bottom of the wells after excitation with 20
flashes per well at 450 nm. Thioflavin-T emission counts
(relative fluorescence units) increased to a maximum limit
of 260,000 per well.
Sucrose density gradient centrifugation (SDGC)
SDGC was performed as described previously [12] to
separate PrPSc aggregates according to their densities from
samples of frontal cortex from VPSPr case 1, and case of
sCJD VV2. Frontal cortex from a non-CJD case was sepa-
rated as a control. Briefly, centrifugation was carried out
in an Optima™ TLX Ultracentrifuge (Beckman Coulter)
using an MLS-50 swinging bucket rotor. The sucrose gra-
dient used was set up in a 5 ml ultracentrifuge tube. Each
step was 745 μl and the dilutions were, from bottom to
top, 60, 30, 25, 20, 15 and 10% sucrose in Tris-buffered sa-
line containing 1% N-lauroylsarcosine. Whole brain hom-
ogenate 5% (w/v) containing 2% N-octyl glucopyranoside
(NOG) in PBS (1X) was clarified and loaded on top of the
sucrose gradient and centrifuged at 4°C and 50,000 g for
1 hr, all as described in [12]. During centrifugation the su-
crose gradient becomes continuous. After centrifugation
11 fractions of 450 μl were collected by pipetting from the
top of the gradient. Therefore, the density of the fractions
increases from 1-11. For western blot analysis, fractionswere PK digested (50 μg/ml PK, 1 h) and precipitated with
nine volumes of methanol overnight at -80°C and pellets
were collected by centrifugation (16000 g for 1 hr). For
RT-QuIC analysis, fraction samples were diluted 1:10 with
PBS containing 0.1% SDS.
Results
D-N values for VPSPr frontal cortex compared with other
prion diseases
Figure 2 shows the D-N values of VPSPr frontal cortex
brain homogenates (mean of samples from five patients).
These values are compared with frontal cortex from pa-
tients with sCJD (of the MM1, MM2 and VV2 subtypes),
variant CJD, and two cases of GSS (both P102L muta-
tion of PRNP). Cases with a diagnosis other than prion
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analysis was performed after no treatment (Figure 2a), or
treatment with 2.5 or 50 μg/ml PK (Figure 2b). In the ab-
sence of PK digestion, CDI is ineffective at discriminating
between prion disease and non-prion disease specimens:
using the mean D-N value for non-CJD cases plus 3 s.d.
as a cut-off value (158 μg PrP per gram brain) only sCJD
VV2 subtype, vCJD and GSS (type 1 PrPres) give values
above this cut-off.
In contrast, CDI could clearly distinguish between prion
disease and non-prion disease specimens after pretrea-
ment of the homogenates with 2.5 μg/ml PK (Figure 2b,
green bars). After this mild PK treatment, the D-N signals
were abolished for non-CJD samples, but high D-N values
were obtained for VPSPr equivalent to those obtained
for sCJD MM1 and sCJD MM2. Using the mean [D-N]
(+3 s.d.) for non-CJD samples pretreated with 2.5 μg/ml
PK as the new cut-off , samples from all prion diseases
apart from GSS (~8 kDa) gave values above this
threshold. The high D-N signals from the VPSPr, CJD
and GSS specimens following denaturation of samples
digested with 2.5 μg/ml PK indicated the presence of
PrPSc that resists mild proteolysis, in contrast to PrPc
which is abolished. Therefore, low concentration PK
treatment allows D-N to distinguish between the prion
disease samples (VPSPr, CJD, GSS) and the non-CJD
group.
High concentration PK treatment (50 μg/ml) abolishes
D-N in the GSS case associated with ~8 kDa PrPres
(Figure 2b, blue bars). However, between 2.5 and
50 μg/ml PK, D-N is maintained in sCJD VV2 subtype
and GSS (type 1 PrPres), but falls in all other prion dis-
eases, the fall being greatest for VPSPr. We can infer
that the decrease in D-N between 2.5 and 50 μg/ml PK
is due to the elimination of poorly protease-resistant
forms of PrPSc, referred to as senPrPSc (Table 1). Alter-
natively, rather than eliminating PrPSc, 50 μg/ml PK
digestion may remove the C-terminal epitope for the
capture antibody, rendering PrPSc undetectable by CDI.
This would be the case if the digestion product was the
~8 kDa fragment observed on western blots for VPSPr
and GSS. It is interesting to note that after 50 μg/ml PK,
very high D-N signals were detected in the GSS (type 1
PrPres) case, in contrast with the GSS (~8 kDa PrPres) case,
in which D-N was completely abolished at 50 μg/ml PK
(Figure 2).
D-N values for frontal cortex versus cerebellum in VPSPr
cases
CDI analysis comparing frontal cortex and cerebellum
for VPSPr cases 1-4, following digestion with 0, 2.5 and
50 μg/ml PK is shown in Figure 3. Similar to frontal
cortex, positive D-N value are obtained for cerebellum
following treatment with 2.5 μg/ml PK (Figure 3, redbars). In the frontal cortex of VPSPr cases 2-4 and in
the cerebellum of VPSPr case 1 and 4, the D-N values are
severely reduced following treatment with 50 μg/ml PK.
For VPSPr cases 2 and 3 the D-N values were considerably
greater for cerebellum versus frontal cortex after 50 μg/ml
PK (Figure 3) suggesting the presence of protease resistant
PrPSc with intact C-termini. In these cases, a marked dis-
tinction had been seen in the western blot PrPres molecular
profile for the frontal cortex (~8 kDa PrPres) and cerebel-
lum (predominantly triple band pattern resembling type
2A PrPres) (Figure 4) [7]. However, in VPSPr case 1,
the western blot profile showed the presence of ~19 and
~23 kDa bands in addition to the ~8 kDa band in the
frontal cortex (Figure 5), and in agreement with this, CDI
analysis showed the preservation of the D-N signal in
frontal cortex after treatment with 50 μg/ml PK.
PMCA of VPSPr PrPSc from frontal cortex and cerebellum
VPSPr cases 2 and 3 described above were used to inves-
tigate the relative potential for PrPSc from the frontal
cortex or the cerebellum to seed the conversion of PrPC
in a PMCA reaction. These cases were selected for this
test because of the extreme differences between frontal
cortex and cerebellum seen in the western blot PrPres
pattern and the D-N values after treatment with 50 μg/ml
PK (Figure 3). No increase in the abundance of the ~8 kDa
PrPres in the frontal cortex was observed after PMCA using
either non-CJD human brain or humanised transgenic
brain substrate (Figure 4). However, the ~19 and ~23 kDa
bands in the VPSPr cerebellum that co-migrate with middle
and lower bands of the type 2A in sCJD (Figure 1B) were
amplified by PMCA using both substrates. Amplification
was apparent as the appearance of a band at ~30 kDa and
an increase in signal for the ~19 and ~23 kDa bands. The
mean increase in signal (VPSPr cases 2 and 3) for the latter
two bands was ~2.6- and 1.5-fold, using human and mouse
brain substrates, respectively. A ~30 kDa band, that may
correspond to diglycosylated PrPres, also appears when
VPSPr frontal cortex samples are amplified by PMCA
(Figure 4). The replicative properties of PrPSc from cases
of GSS associated with either type 1 or ~8 kDa PrPres were
also investigated by PMCA. Densitometric analysis in-
dicated a ~1.5 fold level of amplification, using either
human or mouse brain substrate for GSS with type 1
PrPres in contrast to a lack of amplification for GSS
with an ~8 kDa PrPres, using human and transgenic
mouse brain substrates (Figure 4). In contrast, both the
human brain and humanised transgenic mouse brain
substrates showed robust amplification when seeded
with a sCJD VV2 subtype sample (Figure 4).
Neuropathological correlate
An interesting question is whether the biochemical and
seeding potential differences observed between VPSPr
Figure 3 Comparison of VPSPr frontal cortex and cerebellum by CDI. CDI analysis of samples of frontal cortex or cerebellar cortex homogenate
from VPSPr cases 1-4 following treatment with 0 (red bars), 2.5 (green bars) or 50 μg/ml PK (blue bars) for 1 h. The error bars are S.D. for triplicate
analyses of single samples.
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neuropathology. We were unable to see a clear correlation
between the detection of cerebellar ~19 and 23 kDa PrPres
by western blot, (high is cases 2 and 3) and the number of
cerebellar microplaques between cases (high in cases 2
and 4) (Table 2).- +
FC
VPSPr Case 2
Cb FC Cb
- + - + - +
VPSPr Case 3
human 
substrate
Tg mouse
substrate
VV substrate
Figure 4 PMCA of VPSPr, GSS and sCJD PrPSc. Brain homogenate prepa
and 3, and frontal cortex from two cases of GSS (associated with ~8 kDa an
seed single-round PMCA reactions. The brain homogenates used as substra
post mortem brain frontal cortex tissue (upper panel) or humanised transgen
compatible PRNP-codon 129 genotypes were used (VV in the case of VP
substrate) volume ratios were as follows: VPSPr cases (1:4), GSS and sCJD
The region of the ~8 kDa PrPres band is indicated with a bracket. Separa
shown in lane M.Regional variation in a VPSPr case with extensive
available tissue
Western blot analysis
Unlike the other VPSPr cases identified by surveillance
in the UK, multiple brain regions were available for analysis
from VPSPr case 1 (Table 2). Eleven anatomical regions40kDa
30kDa
20kDa
M
GSS (Type 1) 
- +
FC
- +
FC
GSS (~8kDa) 
- +
FC
sCJDVV2
] ] 
40kDa
30kDa
20kDa
MM substrate
] ] 
red from the frontal cortex (FC) and cerebellum (Cb) of VPSPr cases 2
d type 1 PrPres, respectively) and a case of sCJD VV2 were used to
tes are as indicated in the figure, and were either non-CJD human
ic mouse brain expressing human PRNP (lower panel). Substrates with
SPr and sCJD VV2, and MM for both cases of GSS). The (seed:
cases (1:9). Samples were amplified by PMCA (+) or kept frozen (-).
te immunoblots have been aligned to the molecular mass markers
Figure 5 Western blot analysis. The brain regions analysed were
cerebral cortex (frontal cortex, FC, temporal cortex, TC, parietal cortex,
PC, occipital cortex, OC), cerebellum, (Cb), hippocampus (Hip), thalamus
(Thal), midbrain, pons major (PM), and medulla (Me). Samples were
homogenised in extraction buffer, digested with 50 μg/ml PK, and
separated by gel electrophoresis and immunoblotted using 3F4 as the
primary antibody. Frontal cortex from a case of sCJD VV2 was analysed in
the lane on the far right for both western blots (VV2). The positions of
the molecular mass markers (in kDa) are indicated on the right.
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homogenised and prepared for conventional western blot
analysis. PrPres was widely distributed throughout cortical
and subcortical regions with regional variation in the
relative levels of the ~8 kDa PrPres and two bands that
appeared to co-migrate with the unglycosylated and
mono-glycosylated PrPres bands of the sCJD VV2 subtype
at ~23 and ~19 kDa (Figure 5). The band corresponding
to diglycosylated PrP was not visible. The brain regions
with the highest overall signal intensities were hippocam-
pus > occipital cortex > parietal cortex, whereas PrPres was
largely absent from the medulla and pons. The ~8 kDa
band was predominant in most regions, but its predomin-
ance was highest for the occipital cortex and lowest for
the midbrain and thalamus (Figure 5).
Comparison of D-N values from multiple regions from a
single case of VPSPr
Samples from VPSPr case 1 were taken from exactly the
same anatomical regions as those analysed by westernblotting and analysed by CDI, for both PrPSc stability
and relative levels of PrPSc, as inferred from D-N. These
samples were compared with available samples from the
two GSS cases used above. Samples were homogenised
and underwent digestion with 0, 1, 2.5, 10 or 50 μg/ml
PK. PrPSc was detectable in all VPSPr brain regions apart
from medulla using CDI analysis (Figure 6), which is in
partial agreement with the western blot analysis for
PrPres. The highest D-N values were detected in the
parietal cortex and basal ganglia, and also the occipital
cortex and midbrain. The lowest D-N levels were detected
in the thalamus and medulla. Negligible D-N signals were
obtained for frontal cortex from a case of amyotrophic
lateral sclerosis with frontotemporal lobar dementia
(ALS-FTLD) used as a control (data not shown).
To be detected by CDI the protease resistant PrPSc must
contain the epitope to 3F4 and the C-terminal epitope to
MAR-1 making the ~8 kDa PrPres fragment, characteristic
of VPSPr and GSS cases, undetectable by CDI (Figure 1a).
In GSS (type 1 PrPres) and sCJD VV2 there is CDI de-
tectable material even at the highest 50 μg/ml PK con-
centration. However, in GSS (~8 kDa PrPres) little or
none survives 2.5 μg/ml PK. Regional analysis of VPSPr
case 1 shows them to be intermediate in profile: after
treatment with 50 μg/ml PK, PrPSc remained detectable in
the parietal cortex in a manner that resembles GSS
(type 1 PrPres) and sCJD VV2 subtype (Figure 6), and
after 10 μg/ml PK, PrPSc was detected in midbrain,
basal ganglia and hippocampus. However, a high PK
concentration largely eliminated CDI-detectable PrPSc
from the other regions, and this PK sensitivity there-
fore resembles GSS (~8 kDa PrPres).
Comparison of PrPSc stability in multiple regions from a
single case of VPSPr
PrPSc is insoluble in detergents such as N-lauroylsarcosine
and can be concentrated by centrifugation. We confirm this
here by showing that PrPSc (inferred from positive D-N
values) is pelleted from VPSPr frontal cortex homogenate,
but is absent from the centrifugal pellet obtained from
non-CJD brain homogenate (Additional file 1: Figure S2).
The insoluble pellet can then be used to measure the
stability of VPSPr PrPSc in the absence of PK. Samples
were centrifugally concentrated from 100 μl aliquots of
homogenate, prior to denaturation with increasing con-
centrations of GdnHCl. By increasing the signal for
PrPSc and removing detergent soluble PrP, centrifugal
concentration enabled the determination of PrPSc stability
in regions such as medulla in which PrPSc had been close
to, or below, the limit of detection in the previous CDI
analysis (Figure 6). The equilibrium denaturation curves
for the analysis of brain regions from VPSPr case 1 are
shown in Additional file 1: Figure S3 along with the
[GdnHCl]½ values and the 95% confidence intervals (CI).
Figure 6 CDI analysis of brain regions from a VPSPr case 1 after treatment of the homogenates with various concentrations of PK. The
brain regions analysed were cerebral cortex (frontal cortex, FC, temporal cortex, TC, parietal cortex, PC, occipital cortex, OC), cerebellum, (Cb),
hippocampus (Hip), thalamus (Thal), midbrain, pons major (PM), and medulla (Me). Homogenates were prepared in 2% N-lauroylsarcosine/PBS
and treated with 0, 1, 2.5, 10 or 50 μg/ml PK for 1 h at 37°C. In addition, samples of frontal cortex were analysed from the GSS (~8 kDa PrPres)
case, and samples of frontal cortex and cerebellum were analysed from the GSS (type 1 PrPres) case and a case of sCJD VV2 subtype. The results
are the mean D-N values (+/- S.D.) for triplicate analyses of single samples.
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in Table 3 and Figure 7. Although PrPSc stability analysis
in VPSPr was restricted to a single case (case 1) where
multiple regions were available, extensive analysis of
another human prion disease subtype, vCJD, gives an
indication of the precision of this method. For example,
analysis of vCJD frontal cortex gave a mean [GdnHCl]½
value of 1.678 (S.D., ±0.175) for three separate vCJD cases
[12]. All regions of this VPSPr case (and GSS and sCJD
positive controls) show a simple sigmoidal transition
when unfolded by increasing guanidine concentrations.
The regional [GdnHCl]½ values for this VPSPr case
varied dramatically, being lowest in occipital cortex
([GdnHCl]½ =1.63) and highest in the cerebellum
([GdnHCl]½ =3.52) (Table 3). Analysis of multiple adjacentsamples from frontal cortex and cerebellum from
VPSPr case 1 showed that the difference in the
[GdnHCl]½ values for these regions was statistically
significant (Table 4). In the GSS (type 1 PrPres) case, no
distinction was seen between the stabilities of frontal
cortex and cerebellum PrPSc, although in both cases it
was high compared with PrPSc in the GSS ~8 kDa
PrPres frontal cortex (Table 3). In sCJD VV2 subtype
frontal cortex, PrPSc was more stable than cerebellar
PrPSc, the latter being in the same range as VPSPr
frontal cortex (Table 3). This suggests that the difference
observed in VPSPr case 1 is not an effect of cerebellum
per se, but of the actual stability of the PrPSc that is
present in different neuroanatomical regions of this
VPSPr brain.
Table 3 Summary of [GdnHCl]½ values for brain regions
from the VPSPr case and the GSS cases
Brain region [GdnHCL]½
value
95% confidence interval
for the curve fit.
VPSPr frontal cortex 2.21 0.11
VPSPr temporal cortex 2.01 0.42
VPSPr parietal cortex 2.07 0.39
VPSPr occipital cortex 1.63 0.21
VPSPr Me 2.87 0.35
VPSPr pons 2.92 0.23
VPSPr Midbrain 1.8 0.61
VPSPr cerebellum 3.52 0.11
VPSPr basal ganglia 2.08 0.21
VPSPr Hip 2.2 0.26
VPSPr Thal 2.32 0.31
sCJD VV2 FC 2.44 0.22
sCJD VV2 Cb 1.94 0.1
GSS frontal cortex
(type 1 PrPres case)
2.57 0.06
GSS cerebellum
(type 1 PrPres case)
2.64 0.06
GSS frontal cortex
(~8 kDa frag. case)
1.68 0.36
The [GdnHCl]½ values shown here were obtained from the curve fits shown in
Additional file 1: Figure S3. The data used to obtain the curve fits were from
single samples, or in the case of VPSPr FC, Cb and PC, data merged from the
analyses of 4, 3 or 2 samples, respectively.
Figure 7 Comparison of PrPSc stabilities to GdnHCl
denaturation in various brain regions from a VPSPr and GSS
cases. The [GdnHCl]½ values obtained from various brain regions
from a VPSPr case, two GSS cases (type 1 and ~8 kDa PrPres case)
and a sCJD VV2 case are plotted to scale (units of molar
concentration of GdnHCl) on a vertical axis from [GdnHCl]½ =1.5 M
at the bottom to [GdnHCl]½ =3.5 M. The [GdnHCl]½ values for
VPSPr are shown in red on the left, whereas the GSS and sCJD VV2
values are on the right in green and blue, respectively. [GdnHCl]½
values (along with 95% confidence intervals for the curve fit) are
also listed in Table 3.
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We investigated whether VPSPr could also seed conver-
sion of recombinant PrP in RT-QuIC. After normalising
for the concentration of PrPres (as determined by quanti-
tative western blot), dilutions of either VPSPr case 1 or
sCJD VV2 brain frontal cortex homogenate were used to
seed the RT-QuIC reactions. Both VPSPr and sCJD VV2
brain homogenates seeded conversion. The efficiency of
seeding on the basis of the lag time to a rise in ThT
fluorescence over 60 hours, was lower for VPSPr per
unit PrPres compared with sCJD VV2 (Figure 8). No
conversion was observed for reactions seeded with equiva-
lent dilutions of non-CJD brain homogenate or unseeded
reactions.
RT-QuIC seeding activity of VPSPr and VV2 sCJD after
sucrose density gradient separation (SDGC)
SDGC was used to separate PrPSc aggregates from VPSPr
and sCJD VV2 subtype brain according to the relative
densities of aggregates. Figure 9a shows the direct western
blot analysis of homogenate from a sample of frontal cor-
tex from VPSPr case 1 that was adjacent to the sample
used in the SDGC analysis. Western blot analysis of the
SDGC fractions indicated that sCJD VV2 subtype brain
PrPSc is predominantly in lower (heavier or more dense)fractions as judged by PK digestion and PrPres detection
by western blot (Figure 9b, upper panel). However, VPSPr
PrPSc separates into a ~19 and ~23 kDa PrPres form found
in the lower fractions and an ~8 kDa PrPres form in the
upper (lighter or less dense) fractions as judged by PK
digestion and western blot (Figure 9b, lower panel). No
detectable PrPSc was found in the bottom (most dense)
fraction. Densitometry of the ~8 kDa and 19/23 kDa
PrPres components before (38%:62%) and after (31%:69%)
centrifugation suggests that the balance of these two dis-
tinct PrPres subpopulations is largely unaffected by SDGC.
The fractions obtained following SDGC separation of
samples of VPSPr, sCJD VV2 and non-CJD brain hom-
ogenate were investigated for their seeding potential, using
Table 4 PrPSc stability analysis of multiple samples from
frontal cortex and cerebellum from VPSPr case 1
FC (n = 4) Cb (n = 3) T-Test (FC vs Cb)
[GdnHCl]½ ± S.E. 2.28 ± 0.08 3.60 ± 0.14 P =0.003
The data shown are the mean [GdnHCl]½ values (± standard error) for separate
curve fits obtained from separate samples of frontal cortex (FC) and cerebellum
(Cb) from VPSPr case 1.
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as a measure, seeding potential was associated with a
broad range of densities for both the sCJD VV2 subtype
and VPSPr (Figure 9b). In the case of sCJD VV2, all frac-
tions seeded RT-QuIC. For VPSPr case 1 seeding activity
was markedly reduced in the uppermost fractions (1 and
2) in which the ~8 kDa PrPres was found.
Discussion
Biochemical and functional aspects of the PrPSc types
present in VPSPr
These results firstly show that VPSPr PrPSc is detect-
able by CDI, but only after mild treatment with pro-
teinase K. Therefore VPSPr, in common with all other
human prion diseases, is associated with a misfolded
form of PrP in which the 3F4 epitope (amino acids
106-112) is concealed. After treatment with 2.5 μg/ml
PK, the D-N values for VPSPr were comparable to
those for sCJD, MM1 and MM2, but less than those
obtained for sCJD VV2 subtype, vCJD and GSS (type 1
PrPres).0
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Figure 8 VPSPr PrPSc can seed conversion in RT-QuIC. The reactions w
amount, normalised according the titre of PrPres (units shown are grams Pr
non-CJD brain homogenate (shown as% [w/v]) were used to seed parallel
the quadruplicate reactions were plotted against time (hours).It is interesting to note that in the case of sCJD VV2
and GSS (type 1 PrPres) high D-N signals remained re-
gardless of the concentration of PK used. The particularly
high values obtained for the sCJD VV2 subtype are in
agreement Saverioni et al who showed that VV2 has the
highest PK-resistance among sCJD types and that VPSPr
is much less resistant [20]. However, in our study we have
shown that in a case of GSS (with ~8 kDa PrPres) any CDI
detectable PrPres was eliminated with even mild PK
treatment. Therefore, VPSPr appears to be intermediate
between these two extremes: Although a considerable
proportion of VPSPr PrPSc was sensitive to proteolysis
with high PK, some PrPSc remained.
In two VPSPr cases, the PrPSc detectable after high PK
treatment was considerably greater for cerebellum than
frontal cortex. Western blot analysis of these cases had
previously shown that frontal cortex PrPres was predom-
inantly ~8 kDa, whereas cerebellum PrPres had a triple
band pattern consistent with type 2A PrPres [7]. Inter-
estingly, in VPSPr case 1, bands at ~19 and ~23 kDa,
co-migrating with the lower and middle bands of type
2A PrPres were observed in frontal cortex by western
blotting. These bands were detectable using an antibody
directed against the C-terminus of PrP. CDI analysis of
frontal cortex from VPSPr case 1 following digestion
with 50 μg/ml PK indicated the presence of resistant
PrPSc with an intact C-terminus. Therefore, CDI in
combination with stringent PK digestion is a sensi-
tive method for mapping PrPres in VPSPr that has a45 50 55 60
ere seeded with three 10-fold dilutions of VPSPr or sCJD VV2 brain
Pres per 100 μl reaction volume). As a control, equivalent dilutions of
reactions. Mean ThT fluorescence values (relative fluorescence units) for
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Figure 9 RT-QuIC seeding activity of VPSPr and VV2 sCJD after sucrose density gradient separation. (a) An adjacent sample from VPSPr
frontal cortex to the one analysed below [in (b)] was homogenised to 10% w/v in extraction buffer and analysed by immunoblotting using 3F4
as the primary anti-PrP monoclonal antibody either without prior PK digestion (15 μl) or following digestion with 50 μg/ml PK and centrifugal
concentration (from 100 μl). The densitometric analysis of the ~19 and ~23 kDa bands versus the ~8 kDa band in this sample is superimposed on
the figure. (b) Samples of SDGC fractions from VPSPr case 1 (200 μl) and sCJD VV2 (100 μl) were PK treated (50 μg/ml, 1 h) precipitated overnight
with nine volumes of methanol, and analysed for PrPres by western blotting. The positions of molecular mass markers (in kDa) are indicated on
the right. The collective densitometric analysis of the ~19 and ~23 kDa bands versus the ~8 kDa bands in the SDGC-separated sample is superimposed
on the figure. (c) VPSPr (case 1), sCJD VV2 and non-CJD brain homogenate were separated by sucrose density gradient centrifugation (SDGC).
The gradient used was 10-60% sucrose and after centrifugation eleven fractions of increasing density were successively taken from the top of
the tube (#1 = lowest density, #11 highest density). Duplicate RT-QuIC reactions were seeded with 2 μl samples of 1:10 dilutions of the fractions.
The ThT relative fluorescence values plotted are the means of the duplicate reactions at 40 hours.
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sembles that found in sCJD.
In vitro seeding activity and aggregate size
We are the first to show that brain homogenate from
VPSPr can seed the conversion of PrPC to PrPSc in a
PMCA reaction. When the above mentioned two VPSPr
cases, with extreme differences between frontal cortex
and cerebellum PrPres patterns, were used to seed PMCA
reactions, only the ~19 and ~23 kDa bands present in the
cerebellum were amplified with the additional appearance
of a band at ~30 kDa. Our results indicate cerebellum
and frontal cortex PrPSc have different seeding activ-
ities, with the amplification products of cerebellum
resembling the triple-band pattern of CJD. These re-
sults mirrored the results obtained for GSS (~8 kDa
PrPres) versus GSS (type 1 PrPres), in which only the
latter seeded conversion in PMCA to a low but meas-
urable extent. The different PMCA results obtained for
the two anatomical brain regions in VPSPr and the
subtypes of GSS suggests that different PrPSc isoforms
may give rise to the ~8 kDa band and the type 1 or 2A
PrPres profiles observed by Western blotting, and that
these PrPSc isoforms may have different replicative
properties. An interesting question is whether the bio-
chemical and seeding potential differences observed
between VPSPr frontal cortex and cerebellum reflect
neuropathological observations. We were unable to
demonstrate a correlation between the detection of
~19 and ~23 kDa PrPres and the presence of cerebellar
microplaques between cases. Although our results sug-
gest the co-existence of different PrPSc conformers in
separate anatomical regions of VPSPr brains, we are
unable to state whether they correspond to separate
prion strains. To answer this, it would be necessary to
demonstrate the transmission of different agent strains
to experimental animals inoculated with samples from
separate regions of VPSPr brains.
Both VPSPr and a form of familial CJD associated
with the V180I-129 M haplotype (fCJD-V180I), shared
a similar PrPres electrophoretic profile on western blots
with a low molecular mass band at ~8 kDa [10] and
both lacked diglycosylated PrP and the N181 monogly-
coform. Xiao et al. have suggested that VPSPr and
fCJD-V180I share a pathway for the propagation of
PrPSc in which the conversion of diglycosylated PrPC
and one of the two possible forms of monoglycosylated
PrPC (mono 181) to PrPres is inhibited, which explains the
absence or under-representation of a band co-migrating
with diglycosylated PrPres in the VPSPr electrophoretic
profile [11]. The appearance of a strong diglycosylated
band in the amplified product suggests that in PMCA
this inhibition effect is overcome and that VPSPr PrPSc
is capable of recruiting and converting diglycosylatedand N181 monoglycosylated PrPC to a highly protease-
resistant form resembling that found in CJD.
We have also shown for the first time that VPSPr
brain homogenate has the potential to seed conversion
of recombinant PrP in the RT-QuIC assay. In the single
cases that we examined a lower overall efficiency of con-
version was observed for VPSPr compared with sCJD of
the VV2 subtype. The analysis of a greater number of
cases would be necessary to draw definite conclusions
on the relative seeding potential of VPSPr versus other
human prion disease subtypes. However, different conver-
sion efficiencies between different human prion disease
subtypes have been observed previously in RT-QuIC, with
variant CJD converting very much less efficiently com-
pared with sCJD [15].
For both VPSPr and sCJD VV2 the RT-QuIC seeding
activity was widely dispersed throughout a 10-60% sucrose
gradient, following ultracentrifigation and did not simply
reflect the apparent sedimentation of PrPres to the lower
(more dense) fractions. The sedimentation properties of
PrPSc from this VPSPr case 1 showed some similarities to
those of sCJD VV2: For sCJD VV2, type 2A PrPres was
predominantly found in the lower (heavier or more dense)
fractions. For VPSPr, bands at ~19 kDa and 23 kDa, that
appeared to co-migrate with the lower and middle bands
of type 2A PrPres in sCJD, were also predominantly found
in the lower fractions. However, the ~8 kDa PrPres ap-
peared to have different sedimentation properties and was
confined to the upper (less dense) fractions. This implies
that these two aggregation states (one which is recognised
as ~8 kDa PrPres and the associated with PK –resistant
bands at ~19 kDa and ~23 kDa) differ in size and exist
independently in situ. However, we cannot exclude the
possibility that these two different forms might be disag-
gregated by the mild solubilising effects of the detergent
(NOG) needed for SDGC.
The presence of seeding activity in the upper fractions
suggests that less dense (presumably smaller) forms of
protease sensitive PrPSc, possibly including oligomers,
can provoke PrPC to PrPSc conversion and possibly
contribute to the pathogenesis in human prion dis-
eases. It is interesting to note that VPSPr seeding activity
was reduced in the uppermost two fractions characterised
by ~8 kDa PrPres. The fact that ~8 kDa PrPres also failed of
amplify by PMCA may suggest that the PrPSc conformer
associated with ~8 kDa PrPres may be an “off pathway”
end product of protein misfolding, and perhaps not, as
one might suppose an intermediate between fully protease
sensitive PrPSc and fully protease resistant PrPSc.
VPSPr was first reported in 2008 and to date there are
no published studies of its transmissibility to humanised
transgenic mouse models. This may be taken to imply
that VPSPr is at best poorly transmissible, specifically in
comparison to CJD. The data reported here using in vitro
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that VPSPr transmissibility might be associated with a bio-
chemical profile in VPSPr that partly resembles that found
in CJD.
Regional variation of PrPSc abundance and type
The western blot analysis of regions from VPSPr case 1
showed PrPres to be widespread throughout the brain,
with the highest levels in the parietal cortex, and the
lowest in the medulla and pons. The regional varia-
tions of the upper ~19 kDa and ~23 kDa PrPres bands
and the ~8 kDa PrPres band suggest that these subtypes
display independent variability according the location
within the brain. The degree of difference in the molecular
profile of PrPres from frontal cortex and cerebellum does
however differ between VPSPr cases. This difference was
not a major feature of VPSPr case 1, the only case for
which we had access to a full range of neuroanatomical
regions.
Our study is the first to show a truly widespread distri-
bution of PrPres in a VPSPr brain by western blotting. In
the original description of VPSPr cases, western blot ana-
lysis had been carried out on three subcortical regions
(substantia nigra, putamen and thalamus) in eight cases of
VPSPr and had found readily detectable amounts of PrPres
in only one of these subcortical regions (thalamus) from
one case [3]. In another case report, PrPres was detected
by western blotting as a faint ladder-like pattern of bands
in cerebral cortex and thalamus and as a PrPres pattern re-
sembling the triple band pattern of type 2A in cerebellum
[9]. Based on the positions of the two immunoreactive
bands (~19 and ~23 kDa) that are apparent in the VPSPr
cerebellum of cases 2 and 3, and all anatomical regions
analysed from VPSPr case 1, it is reasonable to conclude
that there are molecular overlaps between VPSPr and
sCJD: These bands appear to co-migrate with the middle
and lower type 2A PrPres bands (Figure 5 and ref [7]) and
have intact C-termini (Additional file 1: Figure S1). How-
ever, it should be noted that, in contrast with sCJD VV2,
there is a clear under-representation of the upper band.
The western blot results for VPSPr case 1, were
reflected in the CDI analysis of the same multiple brain
regions from this case. PrPSc (determined on the basis of
D-N after mild protease treatment) was detected by CDI
in the cerebral cortex, midbrain, hippocampus and basal
ganglia, but was absent in the medulla. In this VPSPr
case, there was a marked reduction, or elimination, of
CDI-detectable PrPSc from many regions following treat-
ment with the highest concentration of PK (50 μg/ml),
whereas in the parietal cortex PrPSc remained. These re-
sults are consistent with the presence of two conformer
classes in this case of VPSPr that have either C-terminal
PK resistance (type 2 PrPres) or C-terminal PK sensitivity
(~8 kDa PrPres).The relative conformational stabilities of PrPSc from
different regions from VPSPr case 1 were also determined
by centrifugal concentration of PrPSc, and the resuspen-
sion and denaturation of the pellet with a range of
GdnHCl concentrations. We have shown that in the
absence of PK, CDI-detectable PrPSc can be recovered
from VPSPr homogenates by virtue of sarkosyl insolubility
and following resuspension and unfolding in various con-
centrations of GdnHCl a sigmoidal transition is seen for
all VPSPr regions and the GSS and sCJD VV2 subtype
positive controls. Differential PrPSc stability was marked
in VPSPr case 1, consistent with different forms or mix-
tures of forms present in different regions.
A marked difference in conformational PrPSc stability
was seen between VPSPr cerebral cortex and cerebellum
with cerebellar PrPSc being apparently much more stable
and a [GdnHCl]½ of ~3.6 M. In contrast, in the sCJD
VV2 subtype case we have shown that a marginally lower
stability ([GdnHCl]½ ~1.9) is obtained for cerebellum com-
pared with frontal cortex (~2.4) (Table 3 and Additional
file 1: Figure S3). No difference in stability was observed
between the frontal cortex and cerebellum for cases of
GSS (type 1 PrPres) and previous studies failed to detect a
marked difference in PrPSc stability between these regions
in GSS [21] and variant CJD [12].
The co-existence of distinct PrPres types (1 and 2A)
has been noted in a significant proportion of sporadic
CJD brains by western blotting [22,23]. Using an alterna-
tive method to CDI, known as conformational stability
immunoassay (CSI) Cali et al have reported different
stabilities for type 1 versus type 2A PrPres in individuals
who are MM at PRNP-codon-129. In MM cases with co-
existent PrPres types a spectrum of PrPSc stabilities were
obtained with values that spanned the region between the
stabilities reported for (non-mixed) type 1 and type 2A
PrPres sCJD cases [22]. However, our study is the first to
report a marked difference in PrPSc stability between two
anatomical regions of the same prion disease brain and
provides further evidence for the existence of PrPSc het-
erogeneity in VPSPr brains.
The relationship of VPSPr to GSS
A similarity had been noted between GSS and VPSPr, in
terms of the PrPres electrophoretic profile and the rela-
tive sensitivities of PrPres fragments within these profiles
to digestion with PK [4,24]. This has led to suggestions
that VPSPr is the sporadic equivalent of GSS, in the same
way that sporadic fatal insomnia (sCJD MM2-Thalamic)
has been proposed to be the sporadic equivalent of fatal
familial insomnia (PRNP D178N Codon-129M). Pirisinu
et al. examined the relationship between VPSPr and GSS
in humans and an atypical form of scrapie in sheep and
goats known as Nor98 [21]. They also compared the con-
formation stabilities of PrPSc from a single brain region
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native method to CDI, known as conformational stability
and solubility assay (CSSA) that measures the diminution
of PrPSc remaining in the detergent insoluble pellet after
treatment with increasing concentrations of GdnHCl. In
agreement with our study, Pirisinu et al determined the
PrPSc stability in VPSPr frontal cortex (PRNP-codon 129
VV) to be [GdnHCl]½ =2.0-2.4 M [21] which they showed
to be midway between the PrPSc stabilities in GSS P102L
(type 1 + ~8 kDa PrPres) and GSS P102L (~8 kDa PrPres).
Our current study and the study by Pirisinu et al. indi-
cate that the biochemical characteristics of PrPSc from the
VPSPr cases did not exactly match the PrPSc phenotypes
observed in GSS, and therefore suggest that VPSPr is a
distinct biochemical entity. A key distinction we observed
in this study is the differing conformational stabilities of
VPSPr PrPSc between cerebral cortex and cerebellum and
no such difference in PrPSc stabilities was observed for a
case of GSS P102L (type 1 PrPres) (Table 3). PrPSc from
VPSPr cerebellum is considerably more stable, and in a
number of VPSPr cases it is associated with PrPres bands
on western blot analysis, that appear to co-migrate with
type 2 PrPres bands observed in sCJD. In contrast, PrPSc
from VPSPr cerebral cortex has a stability and PrPres mo-
lecular profile that is closer to GSS ~8 kDa PrPres cases.
Conclusions
Our analyses indicate the following: Firstly, CDI con-
firms the presence of readily detectable PrPSc in VPSPr
that can be diminished by mild protease treatment.
However, CDI also demonstrates that a proportion of
the PrPSc found in VPSPr resists digestion of its C-
terminus even when high concentrations of protease
are used. This characteristic distinguishes VPSPr from
GSS associated with ~8 kDa PrPres and points to bio-
chemical similarities with sCJD. Some, but not all cases
of VPSPr show in the cerebellum PrPres bands at ~19
and ~23 kDa that co-migrate with the lower and mid-
dle bands of type 2A PrPres in sCJD, instead of, or in
addition to, the ~8 kDa type. It is the former type that
appears to replicate in PMCA. In contrast, little or no
amplification was observed for the ~8 kDa PrPres either
in VPSPr or a case of GSS associated with this PrPres
subtype.
Intensive investigation of a single VPSPr case showed
broad brain region-specific spectrum of protease
sensitivity, differing relative amounts of ~8 kDa PrPres
and ~19 & 23 kDa PrPres, and the stability of PrPSc in
the absence of proteases depending on the brain region
examined. PrPSc was found to be widely distributed
throughout cortical and some subcortical brain regions
in VPSPr. The sedimentation properties and RT-QuIC
seeding activity of PrPSc from VPSPr frontal cortex re-
semble those of CJD.The overall conclusion of this study is that VPSPr is
heterogeneous in terms of protease sensitivity and re-
sistance to denaturation by chaotropes and includes a
proportion of PrPSc with biochemical properties and
functional characteristics similar to those of sCJD. This
heterogeneity exists both between VPSPr cases and be-
tween brain regions within individual cases. Although
this study has focussed on the biochemical aspects of
PrPSc in VPSPr, the heterogeneity that we have observed
may party underlie the neuropathological heterogeneity in
VPSPr cases.
Additional file
Additional file 1: Figure S1. Western blot analysis of VPSPr and sCJD
VV2 using anti-PrP primary antibodies recognising internal and C-terminal
epitopes. Western blot analysis of cerebral cortex homogenate from an
sCJD VV2 case or VPSPr case 1, with (+) or without (-) PK treatment, using
the anti-PrP monoclonal antibodies 3F4 (amino acids 106-112) or 94B4
(C-terminal, amino acids 187-193). The volumes of homogenates analysed
are indicated. Numbers in brackets [] indicate the volumes that were
centrifugally concentrated. Figure S2. D-N and N values for whole brain
homogenate versus centrifugal pellet for VPSPr versus non-CJD. D-N (red
bar) values for brain frontal cortex homogenate and centrifugal pellet
from a case of VPSPr and a non-CJD case (ALS/FTLD). Samples (100ml) of
a 10% (w/v) homogenate of frontal cortex (H) from VPSPr case 1 or a
non-CJD case were analysed directly by CDI. Alternatively, 100μl samples
were centrifuged at 20,000g for 1h at 4°C and the pellets were analysed
by CDI. The results are the means + S.D. for triplicate analyses of single
samples. Figure S3. Equilibrium unfolding analysis. The stability of PrPSc
in various regions of a VPSPr brain, two cases of GSS and a case of sCJD VV2
was investigated by CDI following denaturation with various concentrations
of GdnHCl. The y-axis on this curve is the fraction of PrPSc that is unfolded,
calculated as described in the methods. The abbreviations used for the
various brain regions are the same as in Figure 5. For the analysis of FC, CB
and PC, the data were merged from the analysis of 4, 3 and 2 samples,
respectively. Single samples were analysed for the other regions. FC was
analysed from one GSS case (P102L, small fragment), and Cb and FC was
analysed from another GSS case (P102L, type 1). Underneath each figure is
given the [GdnHCl]1/2 value and the 95% CI for the curve fit.
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